Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Analysts

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have received a consensus rating of “Hold” from the thirteen ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $19.7273.

Several research firms recently commented on BCYC. Royal Bank Of Canada reissued a “sector perform” rating and set a $11.00 target price (down from $27.00) on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Truist Financial began coverage on Bicycle Therapeutics in a research report on Monday, November 24th. They set a “hold” rating and a $10.00 price objective for the company. Citigroup reaffirmed an “outperform” rating on shares of Bicycle Therapeutics in a report on Friday, October 31st. JMP Securities set a $12.00 price target on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday.

Insider Activity at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 3,231 shares of the stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $8.41, for a total value of $27,172.71. Following the transaction, the chief executive officer owned 475,310 shares of the company’s stock, valued at $3,997,357.10. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 8,527 shares of company stock worth $71,738 in the last three months. Insiders own 22.90% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

A number of institutional investors have recently bought and sold shares of BCYC. Assetmark Inc. raised its position in shares of Bicycle Therapeutics by 74.9% during the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after acquiring an additional 1,552 shares in the last quarter. Ausdal Financial Partners Inc. purchased a new position in Bicycle Therapeutics in the second quarter valued at approximately $70,000. Sei Investments Co. acquired a new stake in Bicycle Therapeutics during the second quarter worth approximately $74,000. Virtus Investment Advisers LLC raised its holdings in Bicycle Therapeutics by 32.6% during the second quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock worth $75,000 after purchasing an additional 2,659 shares in the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth approximately $86,000. 86.15% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Stock Up 0.6%

Shares of BCYC opened at $6.99 on Friday. The company has a market cap of $484.55 million, a P/E ratio of -1.93 and a beta of 1.47. Bicycle Therapeutics has a fifty-two week low of $6.03 and a fifty-two week high of $15.47. The firm’s 50 day moving average price is $7.17 and its 200 day moving average price is $7.50.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, October 30th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.24. The business had revenue of $11.73 million during the quarter, compared to the consensus estimate of $8.25 million. Bicycle Therapeutics had a negative net margin of 884.51% and a negative return on equity of 36.05%. Research analysts forecast that Bicycle Therapeutics will post -3.06 earnings per share for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.